Aurobindo Pharma receives tax demand of over Rs 13 crore, including interest, penalty

Published On 2024-05-04 09:41 GMT   |   Update On 2024-05-04 09:41 GMT
Advertisement

New Delhi: Aurobindo Pharma Ltd has been issued a tax demand exceeding Rs 13 crore by the GST authority. This demand encompasses both interest and penalties and relates to the company's ineligible input tax credit claim.

The Deputy Commissioner (ST) STU-1 of GST, Punjagutta Division, Hyderabad, Commercial Taxes Department, Telangana, has passed an order under relevant provisions of the Central Goods and Services Tax Act, 2017 and TGST Act 2017 for the FY 2018-19 demanding reversal of ITC and payment of GST amounting to Rs. 6,54,50,645 along with interest of Rs.5,92,20,900/-. A penalty of Rs. 65,51,354.

Advertisement
It claims ineligible ITC and orders reversal of ITC and demanding GST along with interest, the company stated.

The Company is intending to file appeal before Appellate Authority, Aurobindo Pharma stated in a BSE filing.

Read also: Aurobindo Pharma appoints T Vijaya Kumar as President - RnD (Specialty Drug Delivery)

There is no material impact on the Company financials or operations due to the said order, the Company further added.

Medical Dialogues team had earlier reported that Sun Pharmaceutical Industries had been served with a tax demand of over Rs 1.11 crore by authorities, citing disallowed input tax credit.

Read also: Sun Pharma served with tax demand of Rs 1.11 crore


Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News